FTC Chair Lina Khan (Graeme Jennings/Pool via AP)

FTC opens in­ves­ti­ga­tion in­to largest PBM­s' an­ti­com­pet­i­tive prac­tices

The Fed­er­al Trade Com­mis­sion is turn­ing up the heat on the drug in­dus­try’s mid­dle­men, launch­ing an in­ves­ti­ga­tion in­to phar­ma­cy ben­e­fit man­ag­er prac­tices and the ef­fect on drug prices. The move comes just a few months af­ter a dif­fer­ent study pro­pos­al failed to gain enough sup­port among the FTC com­mis­sion­ers in a 2-2 tie vote.

Now with a re­vamped study and new­ly ap­point­ed Pres­i­dent Biden pick Al­varo Bedoya on board, the com­mis­sion vot­ed unan­i­mous­ly 5-0 to dig in­to PBM prac­tices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.